Sucralfate significantly reduces ciprofloxacin concentrations in serum.
The effect of sucralfate on the bioavailability of ciprofloxacin was evaluated in eight healthy subjects utilizing a randomized, crossover design. The area under the concentration-time curve from 0 to 12 h was reduced from 8.8 to 1.1 micrograms.h/ml by sucralfate (P less than 0.005). Similarly, the maximum concentration of ciprofloxacin in serum was reduced from 2.0 to 0.2 micrograms/ml (P less than 0.005). We conclude that concurrent ingestion of sucralfate significantly reduces the concentrations in serum produced by a 500-mg dose of ciprofloxacin. On the basis of these findings, ciprofloxacin and sucralfate should not be administered concurrently.
Garrelts
J C
JC
Department of Pharmacy, St. Francis Regional Medical Center, Wichita, Kansas.
Godley
P J
PJ
Peterie
J D
JD
Gerlach
E H
EH
Yakshe
C C
CC
D000328:Adult; D001682:Biological Availability; D002939:Ciprofloxacin / Q000097:blood*; D003864:Depression, Chemical; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D013392:Sucralfate / Q000494:pharmacology*
D013392:Sucralfate; D002939:Ciprofloxacin